Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
42 participants
INTERVENTIONAL
2011-11-30
2012-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
DDI Study With Multiple-dose LX4211 and Single Dose Digoxin
NCT02300350
Study to Evaluate the Effect of AMG 510 on the Pharmacokinetics (PK) of Digoxin in Healthy Participants
NCT05598281
Drug Interaction Study of Digoxin and BI 10773
NCT01306175
Study of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy Subjects
NCT00904176
Drug-Drug Interaction Study in Health Adult Volunteers
NCT02273986
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PA21 and Digoxin with food
The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Digoxin will be 0.5 mg/day
PA21
The maximum dose of PA21 will be 15.0 g/day.
Digoxin
The maximum dosage of Digoxin will be 0.5 mg/day
No PA21; Digoxin with food
The maximum dosage of Digoxin will be 0.5 mg/day
Digoxin
The maximum dosage of Digoxin will be 0.5 mg/day
PA21 with food and Digoxin 2hrs later
The maximum dose of PA21 will be 15 g/day. The maximum dose of Digoxin will be 0.5 mg/day
PA21
The maximum dose of PA21 will be 15.0 g/day.
Digoxin
The maximum dosage of Digoxin will be 0.5 mg/day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PA21
The maximum dose of PA21 will be 15.0 g/day.
Digoxin
The maximum dosage of Digoxin will be 0.5 mg/day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Written informed consent
Exclusion Criteria
* Pregnancy
20 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vifor Pharma
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peter Winkle, MD
Role: PRINCIPAL_INVESTIGATOR
ACRI - Phase 1 (Advanced Clinical Research Institute)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ACRI - Phase 1
Anaheim, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PA-DDI-004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.